Solid Dispersion (Kneading) Technique: A Platform for Enhancement Dissolution Rate of Valsartan Poorly Water Soluble Drug

Vinod T. Wagh1*, Ritu M. Gilhotra2, Rajendra D. Wagh3

1Suresh Gyan Vihar University, Mahal, Jagatpura, Jaipur-302025, Rajasthan, India
2Suresh Gyan Vihar University, Mahal, Jagatpura, Jaipur-302025, Rajasthan, India
3A. R. A. College of Pharmacy, Nagaon, Dhule-424005, Maharashtra, India

Received: 23rd Dec, 2019; Revised: 24th Jan, 2020; Accepted: 18th Feb, 2020; Available Online: 25th Mar, 2020

ABSTRACT

The objective of this study was to enhance the dissolution rate of valsartan. Using a solid dispersion (kneading) method with Kollidon and Povidone K30 as a carrier. Eight different drugs: Carrier ratios were prepared. Using factorial design taking 3 factors i.e., the concentration of Valsartan (x1), Kollidon (x2), and Povidone K30 (x3). The enhancement of dissolution depends on the amount of carrier and an increase in the concentration of carrier. Enhancement of dissolution rate depends on reduce particle size of drug place on the surface of carrier and increased wettability of drug particle by carrier. Solid Dispersions prepared with Kollidon as a carrier in ratio 1:4 shows the enhancing dissolution in 30 mins to drug and Physical Mixture. Formulation evaluated by fourier-transform infrared spectroscopy, differential scanning colorimetry, X-ray diffraction, Scanning Electron Microscopy.

Keywords: In-vitro dissolution Kollidon, Povidone K30, Solid Dispersion, Valsartan.

International Journal of Pharmaceutical Quality Assurance (2020); DOI: 10.25258/ijpqa.11.1.3


Source of support: Nil
Conflict of interest: None

INTRODUCTION

Poorly water-soluble drug for oral route formulation is an ongoing challenge for formulation. The bioavailability of drugs depends on the dissolution rate and solubility of drug. These are rate-determining steps for therapeutic activity. The SDs show the best result in enhancement of solubility, wettability, dissolution, and bioavailability. On the surface of carrier deposition of drug lead to reducing in particle size of drug that enhancement of dissolution rate. Larger the surface area of inert carrier that better is release rate. A technique used to the enhancement of solubility, dissolution rate, and bioavailability of poorly water-soluble drug. Valsartan is angiotensin II, receptor antagonist. These effectively use in the treatment of hypertension. Valsartan is poorly water solubility but showing high membrane permeability. Valsartan are considered as class II of drug biopharmaceutical classification system. Improvement in its solubility and dissolution rate leads to the enhancement of bioavailability. Studies on solid dispersion of valsartan have been done using various carriers such as soluplus, gelucire-50/13, cycloexetrin, HPMC, PVP K30, and skimmed milk powder. This main study objective is an enhancement of solubility, the dissolution rate of poorly water-soluble valsartan by using various hydrophilic carriers.

MATERIAL AND METHOD

Material
Valsartan are obtained by a sample from Ranbaxy laboratory; Kollidon was purchased for Research lab chem. Industries, India. Povidone K30 purchased from Pallav chemical Pvt. Ltd, India.

Physical Mixture Prepare (PM)
A physical mixture of Valsartan with Kollidon/Povidone K30 in 1:1 ratio was prepared by mixing of drug and carrier by using mortal and pestle. This mixture passed through mesh no 40. Store in 48h in desiccators.

Solid Dispersion Preparation (SD)
Preparation of solid dispersion using kneading technique. Different eight ratio of drug and carrier 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8 were used. V1 to V8 correspond to preparations containing Kollidon, and V9 to V16 corresponds to preparations containing Povidone K30. Valsartan and Kollidon or Povidone K30 are weighed according to ratio. These are kneaded for 30 minutes using small volume of methanol to give paste, and

*Author for Correspondence: wagh.vinod517@gmail.com
dried at 40°C in oven. These dried mass through sieve no. 30 and store in desiccators 48 hours.

**Determination of Solubility:**
The excess quantity of drug and solid dispersion weighs, and these are put in conical flasks. Flasks are containing 25 mL of phosphate buffer pH 7.4. Sample place in rotary flask shaker for 24 hours. After equilibrium is achieved, solution is diluted. These solutions analyzed by Ultra violet spectroscopy at 250 nm.

**Fourier Transforms Infrared Spectroscopy (FTIR)**
Structural changes and interaction between carrier and drug in the solid dispersions was studied using FTIR spectroscopy. IR spectra of carrier, drug, physical mixture, and SDs were recorded using an FTIR spectrophotometer [Thermo Nicolet 380, USA]. Sample are scanned frequency range 400–4000 cm⁻¹.

**Dissolution Studied**
*In vitro* dissolution studies carried out using Type II dissolution test apparatus, using pH 7.4 phosphate buffers as dissolution media, at a temperature of 37 ± 0.5°C. Speed maintain at 50rpm.

**Differential scanning calorimeter**
Melting behavior of carrier, drug, and SDs was determine by using Differential scanning calorimeter instrument (Mettler Tolado).

**RESULTS AND DISCUSSION**

**Preparation Solid Dispersion of Valsartan and Physical Mixture (PM)**
Three different factors selected that is amount of drug and (Kollidon and Povidone K30) were prepared at two levels, and sixteen batches (F1-F16) of solid dispersion were formulated using factorial design in Table 1.

**Solubility Studies**
Figure 1 represents an increase in drug solubility of SDs over pure drug in phosphate buffer (pH 7.4). Solid dispersion containing Kollidon showed solubility (0.356 mg/mL), a 10 fold increase in solubility as compared to pure drug (0.0050 mg/mL) and Povidone K30 in Figure 2. This may be due to

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Polymer</th>
<th>Drug: Polymer ratio</th>
<th>Formulation code</th>
<th>Polymer</th>
<th>Drug: Polymer ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>PM1</td>
<td>Kollidon</td>
<td>1:1</td>
<td>PM2</td>
<td>Povidone K30</td>
<td>1:1</td>
</tr>
<tr>
<td>V1</td>
<td>Kollidon</td>
<td>1:1</td>
<td>V9</td>
<td>Povidone K30</td>
<td>1:1</td>
</tr>
<tr>
<td>V2</td>
<td>Kollidon</td>
<td>1:2</td>
<td>V10</td>
<td>Povidone K30</td>
<td>1:2</td>
</tr>
<tr>
<td>V3</td>
<td>Kollidon</td>
<td>1:3</td>
<td>V11</td>
<td>Povidone K30</td>
<td>1:3</td>
</tr>
<tr>
<td>V4</td>
<td>Kollidon</td>
<td>1:4</td>
<td>V12</td>
<td>Povidone K30</td>
<td>1:4</td>
</tr>
<tr>
<td>V5</td>
<td>Kollidon</td>
<td>1:5</td>
<td>V13</td>
<td>Povidone K30</td>
<td>1:5</td>
</tr>
<tr>
<td>V6</td>
<td>Kollidon</td>
<td>1:6</td>
<td>V14</td>
<td>Povidone K30</td>
<td>1:6</td>
</tr>
<tr>
<td>V7</td>
<td>Kollidon</td>
<td>1:7</td>
<td>V15</td>
<td>Povidone K30</td>
<td>1:7</td>
</tr>
<tr>
<td>V8</td>
<td>Kollidon</td>
<td>1:8</td>
<td>V16</td>
<td>Povidone K30</td>
<td>1:8</td>
</tr>
</tbody>
</table>

**Powder X-ray Diffraction Studies**
Using of XRD patterns were recorded using BRUKER-axs D8-ADVANCE, model generator Powder, X-ray diffraction patterns, were used to determine intensities and position of diffraction peaks were considered for comparison and identification of crystallinity of the drug or carrier.

**Scanning Electron Microscopy**
Using scanning electron microscopy to determine the external morphology of pure drug and solid dispersion. Solid dispersion was coated with gold-palladium alloy using coat ion sputter.

---

**Figure 1: Solubility of Valsartan, PM1, SDs- Kollidon**

**Table 1: Formulation of solid dispersion**
either the reduction in the crystallinity of drugs or improved wetting of the drug particles.

**Fourier Transforms Infrared Spectroscopy**

FTIR spectrum of valsartan showed its characteristic IR absorption peaks at 1732, 1601, 1470, 1456, 1270, 1202, 1162, 995, 978, 778, 762, 738, 682 and 672 cm\(^{-1}\). Kollidon showed characteristic absorption peaks at 3918, 3902, 3890, 3869, 3863, 3613, 3566, 1683, 1541, 1762, 1507, 666, 643 and 616 cm\(^{-1}\). Povidone K30 showed characteristic absorption peaks at 1646, 1519, 1540, 1418, 1285, 837, 742, 680 and 613 cm\(^{-1}\). Whereas SDs V4 peaks were observed at 3902, 3864, 3838, 3749, 3648, 3566, 1716, 1697, 1541, 1507, 1456, 1418, 708 and 604 cm\(^{-1}\). And SDs V13 peaks were observed at 1660, 1651, 1273, 665, 650, 639, 629, 615 and 607 cm\(^{-1}\) (Figure 3). These spectrum observations indicated no interaction between the drug and carrier used in solid dispersion.

**In vitro dissolution studies**

All the carriers selected showed rapid and higher dissolution of valsartan as compared to pure drug. The dissolution rate observed with various carriers were in following increasing order: Kollidon > Povidone K30. Tables 2 and 3 show the

<table>
<thead>
<tr>
<th>Time</th>
<th>Val</th>
<th>PM1</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V5</th>
<th>V6</th>
<th>V7</th>
<th>V8</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>17.62</td>
<td>19.23</td>
<td>40.9</td>
<td>41.12</td>
<td>41.44</td>
<td>49</td>
<td>45.5</td>
<td>45.21</td>
<td>45.76</td>
<td>45.76</td>
</tr>
<tr>
<td>10</td>
<td>25.31</td>
<td>28.17</td>
<td>45.98</td>
<td>46.21</td>
<td>46.52</td>
<td>52.44</td>
<td>47.48</td>
<td>47.44</td>
<td>47.12</td>
<td>50.63</td>
</tr>
<tr>
<td>15</td>
<td>32.17</td>
<td>36.23</td>
<td>59.1</td>
<td>59.3</td>
<td>59.61</td>
<td>63.7</td>
<td>59.37</td>
<td>63.55</td>
<td>63.11</td>
<td>64.43</td>
</tr>
<tr>
<td>20</td>
<td>35.13</td>
<td>39.12</td>
<td>70.82</td>
<td>71.08</td>
<td>71.38</td>
<td>78.12</td>
<td>75.5</td>
<td>75.32</td>
<td>75.61</td>
<td>75.56</td>
</tr>
<tr>
<td>25</td>
<td>38.12</td>
<td>50.17</td>
<td>85.4</td>
<td>85.61</td>
<td>85.95</td>
<td>90.28</td>
<td>87.88</td>
<td>87.67</td>
<td>87.12</td>
<td>90.32</td>
</tr>
<tr>
<td>30</td>
<td>39.97</td>
<td>59.24</td>
<td>92.02</td>
<td>92.33</td>
<td>92.56</td>
<td>97.89</td>
<td>96.06</td>
<td>95.63</td>
<td>95.87</td>
<td>95</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Val</th>
<th>PM2</th>
<th>V9</th>
<th>V10</th>
<th>V11</th>
<th>V12</th>
<th>V13</th>
<th>V14</th>
<th>V15</th>
<th>V16</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>17.62</td>
<td>18.24</td>
<td>34.74</td>
<td>34.67</td>
<td>34.78</td>
<td>35.22</td>
<td>42.92</td>
<td>42.12</td>
<td>41.6</td>
<td>41.44</td>
</tr>
<tr>
<td>10</td>
<td>25.31</td>
<td>28.32</td>
<td>42.21</td>
<td>43.08</td>
<td>43.28</td>
<td>43.64</td>
<td>47.72</td>
<td>46.43</td>
<td>45.92</td>
<td>45.12</td>
</tr>
<tr>
<td>15</td>
<td>32.17</td>
<td>35.76</td>
<td>55.32</td>
<td>55.65</td>
<td>55.84</td>
<td>56.21</td>
<td>61.34</td>
<td>58.82</td>
<td>58.45</td>
<td>58.13</td>
</tr>
<tr>
<td>20</td>
<td>35.13</td>
<td>39.34</td>
<td>65.78</td>
<td>67.14</td>
<td>67.32</td>
<td>67.69</td>
<td>74.12</td>
<td>71.45</td>
<td>70.56</td>
<td>70.28</td>
</tr>
<tr>
<td>25</td>
<td>38.12</td>
<td>50.11</td>
<td>81.9</td>
<td>82.25</td>
<td>82.44</td>
<td>82.79</td>
<td>86.97</td>
<td>85.12</td>
<td>84.78</td>
<td>84.4</td>
</tr>
<tr>
<td>30</td>
<td>39.97</td>
<td>58.72</td>
<td>89.97</td>
<td>91.12</td>
<td>91.33</td>
<td>91.66</td>
<td>96.21</td>
<td>95.65</td>
<td>95.45</td>
<td>95.02</td>
</tr>
</tbody>
</table>
Solid Dispersion (Kneading) Technique: A Platform for Enhancement Dissolution Rate of Valsartan Poorly Water Soluble Drug

Comparison of the dissolution profile of different formulations of solid dispersions. The aqueous dissolution profile of the SDs of valsartan: Kollidon with different carriers in the ratio of 1:8 is shown in Figure 4 and valsartan: Povidone K30 ratio of 1:8 is shown in Figure 5. SDs of drug with Kollidon as the carrier showed almost 97.89% drug release in 30 mins whereas Povidone K30 as the carrier showed 96.21% drug release, indicating that Kollidon is the most suitable carrier giving better dissolution profile than Povidone K30. Kollidon has a very fine particle size, hence a large surface area. The surface area available for adsorption of drug crystals increases with an increase in the concentration of carrier, leading to an increase in the interfacial area of contact between the drug particles and dissolution media.

Differential Scanning Colorimetry

DSC of valsartan, Carriers, PM, and SDs prepared are shown in Figure 6. Thermogram of drug showed a single sharp endothermic peak at 103.39°C, corresponding to its melting point indicating the crystalline nature of the drug. Kollidon showed an endothermic peak at 104.19°C, whereas SDs with Kollidon as the carrier showed an endothermic peak at 87.39°C. The absence of a melting peak of a drug in the solid dispersion indicated that the drug is entrapped by the carrier, thereby reducing the overall crystallinity of the system. Change in the crystalline structure of drugs in the solid dispersion increased solubility of the drug, which is reflected by the enhanced dissolution rate of the drug from solid dispersion.

X-Ray Diffraction (XRD)

XRD patterns of pure drug, carriers, PM, and solid dispersions are depicted in Figure 7. The diffraction pattern of pure drug valsartan showed a highly crystalline nature, indicated by numerous distinctive peaks at a diffraction angle of 2q (17.92°, 31.66°, 45.52°) throughout the scanning range. XRD of solid surface dispersions showed the disappearance of sharp distinctive peaks at a diffraction angle of 2q (17.78°, 31.73°, 45.42°). The diffraction patterns of the physical mixture and SD indicated changes in the crystalline nature of the drug. The relative 2q angle of valsartan peaks remained unchanged, but the relative intensity of the peaks was decreased. Thus, the relative reduction in the diffraction intensities in the solid dispersions can be attributed to the change in orientation during the crystal growth phase.

Scanning Electron Microscopy (SEM)

The electron microphotographs of pure valsartan and SDs are shown in Figure 8. Figure (a) shows the large smooth surface crystals of pure valsartan. Figure (c) shows SDs of irregular
matrices due to the porous nature of the carrier with fine particles of the drug deposited on it. SEM studies explained the surface morphological properties of the SD, indicating that the solid dispersion is in the amorphous state.

CONCLUSION

Solid dispersion (Kneading) technique was successful in improving the dissolution rate of poorly water-soluble drugs like valsartan. SDs V4 of drug with kollidon as the carrier showed significantly higher dissolution rate as compared to pure drug and physical mixture. The nature and amount of carrier used played an important role in the enhancement of dissolution rate. FTIR and DSC studies showed no evidence of interaction between the drug and carrier.

ACKNOWLEDGMENT

The authors are grateful to M/S Ranbaxy Laboratories (India) for their gift sample of the drug Valsartan.

REFERENCES